Phase 2 N=5 Safety and Performance of the Steroid-Releasing S8 Sinus Implant
Chronic Sinusitis
Primary: Number of Sinuses With Successful Implant Delivery — 10 Sinuses
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=466 A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) (Week 26) — -0.23; 0.17 Percentage (%) of HbA1c — p=<0.0001
Phase 2 N=34 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Complete Response Rate of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) and Pralatrexate (P) Treatment — 52 percentage of participants analyzed
N/A N=24 Effect of Phytochemicals From Theobroma Cacao on Mental Energy
Mental Fatigue
Primary: Correct Responses on Serial 7 Subtraction Task — 40.91; 42.57; 43.04; 42.13 Correct responses — p=0.05
Phase 3 N=577 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
Migraine
Primary: Change From Baseline in Monthly Migraine Days at Week 12 — -1.84; -2.88 migraine days / month — p=< 0.001
N/A N=44 Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies
Coronary Artery Disease · CAD
Primary: Diagnostic Performance (Specificity and Sensitivity) for Detection of Myocardial Perfusion Deficits on Magnetic Resonance (MR) Images — 95; 94 percentage of true cases
Phase 3 N=1,389 Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis
Cerebral Edema · Diabetic Ketoacidosis
Primary: the Number of Participants With Glasgow Coma Score (GCS) < 14 Within the First 24 Hours of Treatment for Diabetic Ketoacidosis (DKA) — 10; 11; 11; 16 Participants — p=0.34
Phase 2 N=32 Bevacizumab in Treating Patients With Angiosarcoma
Sarcoma
Primary: Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria. — 12.4 Weeks
Phase 2 N=111 A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) — 3.0; 4.3; 3.8; 4.8 percentage of participants
Phase 2 N=667 A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
Treatment for Prevention of Chronic Migraine
Primary: Change From Baseline in Monthly Migraine Days — -4.18; -6.64; -6.63 migraine days / month — p=<0.001
Phase 4 N=26 Scopolamine Patch Pharmacokinetics in Healthy Adults
Healthy
Primary: Measurement of Maximum Serum Concentration of Scopolamine (Cmax) — 0.14; 2.63 ng/ml
Phase 3 N=23 A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
Neurogenic Detrusor Overactivity · Pediatric
Primary: Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) — 37.0 mL — p=<0.001
Phase 4 N=144 Surgical Conditions During Laparoscopic Bariatric Surgery
Morbid Obesity
Primary: Surgeon Satisfaction Scale — 2.7; 4.1; 3.1; 4.6 Scores on a scale
Phase 2 N=188 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Summary of Injection Site Reactions for the Safety Population Over the 12-months Post Vaccination Period — 72; 79; 10; 25 AEs
N/A N=78 CYP2B6 Polymorphisms in Methadone Disposition
Healthy Volunteers
Primary: Methadone Metabolism — 0.082; 0.073; 0.054 ratio — p=<0.05